FY2025 Earnings Estimate for MDGL Issued By B. Riley

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – B. Riley decreased their FY2025 earnings per share (EPS) estimates for Madrigal Pharmaceuticals in a report released on Tuesday, November 4th. B. Riley analyst W. Wood now forecasts that the biopharmaceutical company will earn ($8.24) per share for the year, down from their previous forecast of ($4.91). B. Riley currently has a “Buy” rating and a $560.00 target price on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share. B. Riley also issued estimates for Madrigal Pharmaceuticals’ Q4 2025 earnings at $1.96 EPS, Q1 2026 earnings at $3.02 EPS, Q2 2026 earnings at $4.40 EPS, Q3 2026 earnings at $4.84 EPS, FY2026 earnings at $17.54 EPS, FY2027 earnings at $29.89 EPS and FY2028 earnings at $56.96 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.01) by ($3.07). The firm had revenue of $287.27 million during the quarter, compared to analyst estimates of $244.33 million. Madrigal Pharmaceuticals had a negative net margin of 54.68% and a negative return on equity of 38.38%.

Several other equities analysts also recently weighed in on the stock. Citizens Jmp raised their target price on shares of Madrigal Pharmaceuticals from $485.00 to $527.00 and gave the company a “market outperform” rating in a report on Wednesday. Cantor Fitzgerald upgraded shares of Madrigal Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research report on Tuesday. Canaccord Genuity Group lifted their price objective on Madrigal Pharmaceuticals from $428.00 to $526.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Piper Sandler upped their target price on Madrigal Pharmaceuticals from $400.00 to $540.00 and gave the company an “overweight” rating in a research note on Wednesday, October 15th. Finally, UBS Group reissued a “buy” rating and set a $523.00 price target (up previously from $458.00) on shares of Madrigal Pharmaceuticals in a research report on Tuesday, August 12th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $528.42.

Madrigal Pharmaceuticals Stock Up 2.7%

Shares of NASDAQ:MDGL opened at $488.58 on Friday. Madrigal Pharmaceuticals has a fifty-two week low of $265.00 and a fifty-two week high of $496.98. The company has a quick ratio of 4.78, a current ratio of 5.11 and a debt-to-equity ratio of 0.17. The firm’s 50-day simple moving average is $436.11 and its 200-day simple moving average is $356.34. The company has a market cap of $10.85 billion, a price-to-earnings ratio of -38.02 and a beta of -1.04.

Insider Buying and Selling

In other Madrigal Pharmaceuticals news, Director Rebecca Taub sold 43,263 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $355.69, for a total transaction of $15,388,216.47. Following the transaction, the director owned 461,044 shares of the company’s stock, valued at $163,988,740.36. This represents a 8.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Bros. Advisors Lp Baker acquired 68,618 shares of the firm’s stock in a transaction dated Monday, August 18th. The shares were acquired at an average price of $364.04 per share, for a total transaction of $24,979,696.72. Following the acquisition, the director directly owned 1,859,091 shares of the company’s stock, valued at approximately $676,783,487.64. The trade was a 3.83% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 165,683 shares of company stock worth $61,921,142 and sold 248,642 shares worth $91,388,103. Insiders own 21.50% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its stake in shares of Madrigal Pharmaceuticals by 131.4% during the 1st quarter. GAMMA Investing LLC now owns 118 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 67 shares during the last quarter. D.A. Davidson & CO. increased its position in Madrigal Pharmaceuticals by 203.9% during the first quarter. D.A. Davidson & CO. now owns 2,173 shares of the biopharmaceutical company’s stock worth $720,000 after purchasing an additional 1,458 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Madrigal Pharmaceuticals by 1.0% in the 1st quarter. Bank of New York Mellon Corp now owns 60,789 shares of the biopharmaceutical company’s stock worth $20,135,000 after purchasing an additional 579 shares during the period. Envestnet Asset Management Inc. raised its position in Madrigal Pharmaceuticals by 1.8% in the first quarter. Envestnet Asset Management Inc. now owns 15,270 shares of the biopharmaceutical company’s stock valued at $5,058,000 after purchasing an additional 269 shares during the period. Finally, Xponance Inc. grew its position in Madrigal Pharmaceuticals by 7.2% in the first quarter. Xponance Inc. now owns 1,359 shares of the biopharmaceutical company’s stock valued at $450,000 after acquiring an additional 91 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.